Mylan Inc. (MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Ltd., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Lansoprazole Delayed-release Capsules, 15 mg and 30 mg. Lansoprazole Delayed-release Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid DR Capsules.
The company said the product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.
For comments and feedback: editorial@rttnews.com